BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 34799964)

  • 1. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
    Jorgenson MR; Kleiboeker H; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
    Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
    Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
    Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
    Limaye AP; Budde K; Humar A; Vincenti F; Kuypers DRJ; Carroll RP; Stauffer N; Murata Y; Strizki JM; Teal VL; Gilbert CL; Haber BA
    JAMA; 2023 Jul; 330(1):33-42. PubMed ID: 37279999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
    Rho E; Näf B; Müller TF; Wüthrich RP; Schachter T; von Moos S
    Clin Transplant; 2021 Nov; 35(11):e14401. PubMed ID: 34181768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation.
    Jorgenson MR; Wong C; Descourouez JL; Saddler CM; Smith JA; Mandelbrot DA
    Transpl Infect Dis; 2021 Aug; 23(4):e13617. PubMed ID: 33866643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letermovir prophylaxis in solid organ transplant-Assessing CMV breakthrough and tacrolimus drug interaction.
    Winstead RJ; Kumar D; Brown A; Yakubu I; Song C; Thacker L; Gupta G
    Transpl Infect Dis; 2021 Aug; 23(4):e13570. PubMed ID: 33469975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
    Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
    Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.
    Saltiel G; Faure E; Assaf A; Chopin MC; Moreau F; Faure K; Goeminne C; Vuotto F
    Clin Transplant; 2024 May; 38(5):e15327. PubMed ID: 38686437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.
    Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S
    Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.
    Saullo JL; Baker AW; Snyder LD; Reynolds JM; Zaffiri L; Eichenberger EM; Ferrari A; Steinbrink JM; Maziarz EK; Bacchus M; Berry H; Kakoullis SA; Wolfe CR
    J Heart Lung Transplant; 2022 Apr; 41(4):508-515. PubMed ID: 35031206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.
    Razonable RR
    Clin Microbiol Infect; 2023 Sep; 29(9):1144-1149. PubMed ID: 36963566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients.
    Phoompoung P; Ferreira VH; Tikkanen J; Husain S; Viswabandya A; Kumar D; Humar A
    Transplantation; 2020 Feb; 104(2):404-409. PubMed ID: 32000236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letermovir treatment for CMV infection in kidney and pancreas transplantation: A valuable option for complicated cases.
    Ortiz F; Lempinen M; Aaltonen S; Koivuviita N; Helanterä I
    Clin Transplant; 2022 Feb; 36(2):e14537. PubMed ID: 34797574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients.
    Golob S; Batra J; DeFilippis EM; Uriel M; Carey M; Gaine M; Mabasa A; Fried J; Raikelkar J; Restaino S; Hi Lee S; Latif F; Yuzefpolskaya M; Colombo PC; Choe J; Majure D; Jennings D; Pereira MR; Clerkin K; Sayer G; Uriel N
    Clin Transplant; 2022 Dec; 36(12):e14808. PubMed ID: 36086937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction.
    Jorgenson MR; Descourouez JL; Saddler CM; Smith JA; Odorico JS; Rice JP; Mandelbrot DA
    Clin Transplant; 2023 Dec; 37(12):e15142. PubMed ID: 37755141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case Report of Successful Use of Twice-Daily Letermovir in the Treatment of Resistant Cytomegalovirus in a Small Bowel Transplant Recipient.
    Joharji H; Alaidaros F; Koujan H; Hamad A; Almaghrabi RS; Zidan A; Broering D; Al-Jedai A
    Transplant Proc; 2022; 54(6):1679-1681. PubMed ID: 35842318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of a cytomegalovirus-specific T cell assay in assessing the risk of post-prophylaxis cytomegalovirus infection and post-treatment relapse.
    Dioverti MV; Bhaimia E; Yetmar ZA; Melendez DP; Misner L; Beito E; Deziel PJ; Theel ES; Razonable RR
    Clin Transplant; 2023 Dec; 37(12):e15143. PubMed ID: 37805968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letermovir as Cytomegalovirus Prophylaxis in a Pediatric Cohort: A Retrospective Analysis.
    Kuhn A; Puttkammer J; Madigan T; Dinnes L; Khan S; Ferdjallah A; Kohorst M
    Transplant Cell Ther; 2023 Jan; 29(1):62.e1-62.e4. PubMed ID: 36244677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.